ArticleJHEP reports : innovation in hepatology2023
Use of albumin infusion for cirrhosis-related complications: An international position statement.
Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06483737 (Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy), which is not on this map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE): an Invesitgator-initiated, Open-label, Multicenter, Randomized Controlled Trial
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Low-Dose vs. Standard Care Iv Human Albumin During Large-Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Effect of human albumin infusion on inflammation, oxidative stress, and prognosis in decompensated cirrhosis: a prospective cohort study with a meta-analysis.BMC gastroenterology · 2026Pooled it
- Association of non-selective β blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.Hepatology international · 2024Guideline
- Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.Digestive diseases and sciences · 2026Trial
- Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- Association of Early Albumin Administration with Clinical Outcomes in Patients Hospitalized with Spontaneous Bacterial Peritonitis: A Propensity-Matched Cohort Study.Reports (MDPI) · 2026Article
- Post-splenectomy early biochemical trajectories and predictors in 935 patients with Wilson disease: a group-based trajectory modeling study.BMC gastroenterology · 2026Article
- Use of albumin in patients with hepatic encephalopathy: A systematic review and meta-analysis of randomized controlled studies with trial sequential analysis.Hepatology forum · 2026Review
- Binding and transport functions of human serum albumin and its clinical implications in liver disease: a narrative review.Translational gastroenterology and hepatology · 2026Review
- Clinical Perspectives on Long-Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain-The ALBA Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- A retrospective study on the use of albumin in the management of complications of decompensated cirrhosis from a major teaching hospital in Canada.Canadian liver journal · 2025Article
- Review
- Machine learning based CAGIB score predicts in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding.NPJ digital medicine · 2025Article
- The Efficacy of Albumin Infusion in Septic Patients with Hypoalbuminemia: An International Retrospective Observational Study.Journal of clinical medicine · 2025Article
- Immune Dysfunction and Infection Risk in Advanced Liver Disease.Gastroenterology · 2025Review
- Article
- Infection risk and management in patients with cirrhosis: A critical overview.World journal of hepatology · 2025Article
- Understanding acute kidney injury in cirrhosis: Current perspective.World journal of hepatology · 2025Review
- Real-world experience with long-term albumin in patients with cirrhosis and ascites.JHEP reports : innovation in hepatology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
34 authors at 20 institutions in 17 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Numerous studies have evaluated the role of human albumin (HA) in managing various liver cirrhosis-related complications. However, their conclusions remain partially controversial, probably because HA was evaluated in different settings, including indications, patient characteristics, and dosage and duration of therapy. Methods: Thirty-three investigators from 19 countries with expertise in the management of liver cirrhosis-related complications were invited to organise an International Special Interest Group. A three-round Delphi consensus process was conducted to complete the international position statement on the use of HA for treatment of liver cirrhosis-related complications. Results: Twelve clinically significant position statements were proposed. Short-term infusion of HA should be recommended for the management of hepatorenal syndrome, large volume paracentesis, and spontaneous bacterial peritonitis in liver cirrhosis. Its effects on the prevention or treatment of other liver cirrhosis-related complications should be further elucidated. Long-term HA administration can be considered in specific settings. Pulmonary oedema should be closely monitored as a potential adverse effect in cirrhotic patients receiving HA infusion. Conclusions: Based on the currently available evidence, the international position statement suggests the potential benefits of HA for the management of multiple liver cirrhosis-related complications and summarises its safety profile. However, its optimal timing and infusion strategy remain to be further elucidated. Impact and implications: Thirty-three investigators from 19 countries proposed 12 position statements on the use of human albumin (HA) infusion in liver cirrhosis-related complications. Based on current evidence, short-term HA infusion should be recommended for the management of HRS, LVP, and SBP; whereas, long-term HA administration can be considered in the setting where budget and logistical issues can be resolved. However, pulmonary oedema should be closely monitored in cirrhotic patients who receive HA infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.